Aktis Oncology, Inc. Common stock (AKTS) Stock Price

AKTSStock

$25.78−82.46%52W

Market Cap$1.43B

P/E—

PEG Ratio—

Div yield—

Beta121.85

AKTS Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)16.97%

Price vs S&P 500 (4W)14.43%

VGM Score64.62

P/CF (Annual)79.59x

Book Value / Share (Quarterly)$9.48

P/TBV (Annual)0.80x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)147.45%

Price vs S&P 500 (YTD)4.24%

Gross Margin (TTM)-11.60%

Net Profit Margin (TTM)-843.85%

EPS (TTM)$-1.64

10-Day Avg Trading Volume0.32M

EPS Excl Extra (TTM)$-1.64

Revenue Growth (5Y)86.32%

EPS (Annual)$-1.26

ROI (Annual)-34.03%

Gross Margin (Annual)-11.49%

Net Profit Margin (5Y Avg)-443.97%

Cash / Share (Quarterly)$10.08

Revenue Growth QoQ (YoY)100.43%

ROA (Last FY)-24.06%

Revenue Growth TTM (YoY)49.91%

EBITD / Share (TTM)$-1.89

ROE (5Y Avg)-68.61%

Operating Margin (TTM)-1001.54%

Cash Flow / Share (Annual)$-1.46

P/B Ratio2.60x

P/B Ratio (Quarterly)1.89x

Net Income / Employee (Annual)$-806,700

EPS Growth QoQ (YoY)16.66%

EPS Incl Extra (Annual)$-1.26

Current Ratio (Annual)7.37x

Quick Ratio (Quarterly)19.29x

3-Month Avg Trading Volume0.33M

52-Week Price Return-82.46%

EV / Free Cash Flow (Annual)95.61x

Revenue / Employee (TTM)$123,100

Tangible BV / Share (Quarterly)$0.53

P/S Ratio (Annual)202.41x

Asset Turnover (Annual)0.02x

52-Week High$34.19

Operating Margin (5Y Avg)-431.94%

EPS Excl Extra (Annual)$-1.26

CapEx CAGR (5Y)10.40%

Tangible BV CAGR (5Y)32.95%

26-Week Price Return28.90%

Quick Ratio (Annual)7.26x

13-Week Price Return26.19%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)19.49x

Enterprise Value$943.42M

Revenue / Share Growth (5Y)49.17%

Asset Turnover (TTM)0.21x

Book Value / Share Growth (5Y)13.89%

Revenue / Employee (Annual)$82,200

Inventory Turnover (Annual)5.19x

Pretax Margin (Annual)-980.93%

Cash / Share (Annual)$4.48

3-Month Return Std Dev74.07%

Gross Margin (5Y Avg)-21.94%

Net Income / Employee (TTM)$-1,038,700

ROE (Last FY)-34.03%

Net Interest Coverage (Annual)-48.09x

EPS Basic Excl Extra (Annual)$-1.26

Receivables Turnover (TTM)8.26x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-1.64

Receivables Turnover (Annual)6.35x

ROI (TTM)-53.11%

P/S Ratio (TTM)135.24x

Pretax Margin (5Y Avg)-452.15%

Revenue / Share (Annual)$0.13

Tangible BV / Share (Annual)$0.78

Free OCF CAGR (5Y)30.87%

Price vs S&P 500 (52W)-84.50%

EPS Growth TTM (YoY)19.36%

Year-to-Date Return15.09%

5-Day Price Return-0.77%

EPS Normalized (Annual)$-1.26

ROA (5Y Avg)-46.94%

Net Profit Margin (Annual)-980.93%

Month-to-Date Return16.81%

Cash Flow / Share (TTM)$-0.78

EBITD / Share (Annual)$-1.43

Operating Margin (Annual)-1149.52%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-51.05%

LT Debt / Equity (Quarterly)62.67x

EPS Basic Excl Extra (TTM)$-1.64

P/TBV (Quarterly)1.16x

P/B Ratio (Annual)5.88x

Inventory Turnover (TTM)5.95x

Pretax Margin (TTM)-843.85%

Book Value / Share (Annual)$3.70

Price vs S&P 500 (13W)24.23%

Beta121.85x

P/FCF (Annual)110.51x

Revenue / Share (TTM)$0.20

ROE (TTM)-47.53%

52-Week Low$14.72

gGradeB

mGradeC

vgmGradeB

AKTS Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 13, 2026	-$0.43	-$0.44	-2.15%(-$0.01)
Q1 2026	May 11, 2026	-$0.33	-$0.38	-15.15%(-$0.05)

AKTS Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.33

4.38

Industry Peers — Pharmaceuticals(570)

Symbol	Value Score	Growth Score	Momentum Score	Price
AKTSAktis Oncology, Inc. Common stock	—	B	C	$25.78
LLYEli Lilly & Co.	D	B	C	$1174.61
JNJJohnson & Johnson	D	C	B	$268.04
ABBVABBVIE INC.	D	C	B	$255.48
MRKMerck & Co., Inc.	D	C	B	$148.35
NVSNovartis AG	C	C	C	$153.81
AZNAstraZeneca PLC	C	B	C	$162.70
NVONovo-Nordisk A/S	B	C	C	$45.61
ABTAbbott Laboratories	C	C	C	$112.47
PFEPfizer Inc.	C	D	B	$27.96
VRTXVertex Pharmaceuticals Inc	D	C	B	$541.69
BMYBristol-Myers Squibb Co.	B	B	B	$66.58
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$44.82
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$50.82
REGNRegeneron Pharmaceuticals Inc	C	C	B	$794.19
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	B	$18.03
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$36.44
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	$366.73
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$60.85
ZTSZOETIS INC.	C	C	D	$77.34
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$237.10
INSMInsmed, Inc.	F	A	C	$118.54
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$34.71
UTHRUnited Therapeutics Corp	C	C	B	$515.46
GMABGenmab A/S ADS	C	C	B	$33.23
VTRSViatris Inc. Common Stock	B	C	B	$16.34
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$247.91
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$244.54
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$76.60
BMRNBioMarin Pharmaceuticals Inc	C	C	B	$64.67
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	B	$533.76
CORTCorcept Therapeutics Inc.	F	C	B	$113.88
ELANElanco Animal Health Incorporated Common Stock	C	B	C	$24.11
ARWRArrowhead Research Corporation	D	A	B	$84.91
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.73
AXSMAxsome Therapeutics, Inc	D	B	C	$199.02
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.18
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$61.05
CYTKCytokinetics Inc.	F	D	C	$72.09
ABVXAbivax SA American Depositary Shares	—	—	C	$113.35
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$344.75
PTGXProtagonist Therapeutics, Inc	F	B	B	$144.33
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.84
TGTXTG Therapeutics, Inc.	D	B	B	$53.93
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	$90.36
ALKSAlkermes Inc. plc	D	C	B	$47.41
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$107.17
ERASErasca, Inc. Common Stock	—	—	A	$18.03
TVTXTravere Therapeutics, Inc. Common Stock	F	B	A	$65.67
BLTEBelite Bio, Inc American Depositary Shares	—	—	C	$151.72

About Aktis Oncology, Inc. Common stock

Aktis Oncology is a clinical-stage oncology company developing targeted alpha radiopharmaceuticals for solid tumors, including breast, lung, colorectal, bladder, and liver cancers. The company focuses on expanding access to large patient populations not addressed by existing platform technologies. Its pipeline includes AKY-1189 and AKY-2519.